News

 

Nerviano Medical Sciences to Present Preliminary Phase 1 PARP1 selective inhibitor data at the 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Nerviano Medical Sciences to Present Preliminary Phase 1 PARP1 selective inhibitor data at the 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

NERVIANO, IT and BOSTON, Mass, October 2, 2023 – Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today it will present initial data from the PARP1 inhibitor Phase 1 studies at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15 in Boston, MA.

(Click the title for the complete article)

Nerviano Medical Sciences S.r.l. to present data on its ADC platform at the World ADC Summit  2023 in San Diego CA (Oct 16th-Oct 19th, 2023)

Nerviano Medical Sciences S.r.l. to present data on its ADC platform at the World ADC Summit 2023 in San Diego CA (Oct 16th-Oct 19th, 2023)

Nerviano Medical Sciences S.r.l., a member of NMS Group S.p.A and a clinical stage biotech discovering and developing innovative therapies for the treatment of cancer, is proud to announce its participation to the World ADC 2023 summit that will be held in San Diego (CA) from October 16th to October 19th, 2023, with two poster presentations

(Click the title for the complete article)

Nerviano Medical Sciences S.r.l. announces preclinical data on NMS-P945, its novel proprietary payload-linker for ADC generation, published in Molecular Cancer Therapeutics

Nerviano Medical Sciences S.r.l. announces preclinical data on NMS-P945, its novel proprietary payload-linker for ADC generation, published in Molecular Cancer Therapeutics

Nerviano, September 20, 2023 –  Nerviano Medical Sciences S.r.l. (NMS), a member of NMS Group S.p.A.  and a clinical stage biotech, discovering and developing innovative therapies for the treatment of cancer, today announces the publication of preclinical data on NMS-P945  (link to article), its novel protease-cleavable thienoduocarmycin derivative payload-linker, with DNA damaging properties, in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.

(Click the title for the complete article)

Nerviano Medical Sciences S.r.l. names Alberto Ocana, PhD, as Global Clinical Lead

Nerviano Medical Sciences S.r.l. names Alberto Ocana, PhD, as Global Clinical Lead

NMS Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that Alberto Ocana PhD, has joined the Global Clinical Development Team as Global Clinical Lead, effective immediately. In this pivotal role, Alberto will spearhead the company’s efforts to drive innovation, enhance patient outcomes, and strengthen our global partnerships.

(Click the title for the complete article)

Nerviano Medical Sciences Announces Enhanced US Executive Team: Terrence West, MBA, Expands Role as Chief Operating Officer

Nerviano Medical Sciences Announces Enhanced US Executive Team: Terrence West, MBA, Expands Role as Chief Operating Officer

NERVIANO, IT and BOSTON, Mass., August 1, 2023 – Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group), focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today the expansion of and transition in its executive team of its wholly owned U.S. subsidiary (Nerviano Medical Sciences, Inc./ NMS-US) in Boston. Terrence West, MBA, the company’s New Business, Virtual CEO has been appointed to the newly created position of Chief Operating Officer, effective immediately, to further drive the growth of NMS-US while continuing to oversee the strategic positioning of NMS-173, its IDH1/IDH2 Inhibitor Asset.

(Click the title for the complete article)

Nerviano Medical Sciences Announces FDA Clearance of Investigational New Drug (IND) for NMS-03592088 in positive Relapsed or Refractory Acute Myeloid Leukemia

Nerviano Medical Sciences Announces FDA Clearance of Investigational New Drug (IND) for NMS-03592088 in positive Relapsed or Refractory Acute Myeloid Leukemia

Nerviano 22 June 2023_Nerviano Medical Sciences Srl (NMS), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, is delighted to announce the FDA Clearance of Investigational New Drug (IND) Application for NMS-03592088 (NMS-088), a novel, potent FLT3 inhibitor.

(Click the title for the complete article)

Nerviano Medical Sciences S.r.l. to Present MPSA-153-001 at ASCO 2023: Slide deck, Poster and Video Preview

Nerviano Medical Sciences S.r.l. to Present MPSA-153-001 at ASCO 2023: Slide deck, Poster and Video Preview

Nerviano, 26 May 2023 – Nerviano Medical Sciences Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, published a poster today, describing the currently enrolling phase II part of the trial MPSA-153-001, will be presented at the upcoming ASCO Annual Meeting which will be held June 2-6, 2023 at the McCormick Place, Chicago, IL.

(Click the title for the complete article)

 

Welcome and Check out our new motion picture!

WATCH OUR VIDEO